Considering Neoadjuvant Chemotherapy Options in Bladder Cancer

Video

In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.

In this peer-to-peer discussion, Petros Grivas, MD, PhD, of the Cleveland Clinic in Cleveland, Ohio, and Phillip L. Palmbos, MD, PhD, of the University of Michigan in Ann Arbor, Michigan, examine the role of neoadjuvant chemotherapy in bladder cancer, weighing the various trial data that guide these treatment decisions, with considerations for patient comorbidities.

Financial Disclosure:Dr. Grivas is a consultant for Genentech.

 

Recent Videos
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content